Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q2 FY23 Earnings Presentation
27 slides from Dishman Carbogen Amcis's earnings presentation, Nov 11, 2022
Slide 1: Cover letter to stock exchanges
11th November, 2022 To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, “Exchange Plaza”, C-1, Block G, Mumbai – 400 001. Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref.: Scrip Code
Slide 2: Quarter ended September 30th, 2022
Quarter ended September 30th, 2022 November 2022
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward- looking statements, which may include statements relating to future results o
Slide 4: Dishman in a Nutshell
Dishman in a Nutshell 4 decades 2,200+ Team Strength 25 28 Committed Members Embracing of Long-Standing Track Record in our Culture of Innovation & Sustainability CRAMS Dedicated Team/Scientist Working Multi-Purpose MANUFACTURING RESEARCH & DEVELOPMENT APIS in R&D - 950+ FACILITIES Globally and HIPO
Slide 5: Past Performance at a Glance
Past Performance at a Glance Revenue from Operations (₹ mn) EBITDA and EBITDA % Cash Profit (₹ mn) 21,407 EBITDA EBITDA % 4,499 20,586 20,436 4,087 19,120 5,519 3,660 16,948 4,976 3,400 4,453 3,937 2,538 26.8% 24.3% 2,744 18.4% 26.3% 14.3% FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22^ FY18 FY19
Slide 6: Agenda
AGENDA 01 Quarter Highlights 02 Company Overview 03 Industry Overview 5
Slide 7: Quarter Highlights
Dishman Carbogen Amcis QUARTER
Slide 8: Q2 FY23 Result Highlights
Q2 FY23 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN* 6,140 5,406 4,589 992 904 823 21.6% 16.7% 13.4% Q2FY22 Q1FY23 Q2FY23 Q2FY22 Q1FY23 Q2FY23 ADJUSTED PBT# (₹ mn) & PBT MARGIN CASH PAT@ (₹ mn) & CASH EPS (₹) 9.4% 4.0% 5.4 432 4.5 4.1 1.6% 843 218 693 648 98 Q2FY22 Q1FY23 Q2FY
Slide 9: H1 FY23 Result Highlights
H1 FY23 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN* 11,546 10,096 1,999 1,727 19.8% 15.0% H1FY22 H1FY23 H1FY22 H1FY23 ADJUSTED PBT# (₹ mn) & PBT MARGIN CASH PAT@ (₹ mn) & CASH EPS (₹ ) 8.8% 11.0 8.5 2.7% 1,715 1,342 893 316 H1FY22 H1FY23 H1FY22 H1FY23 *EBITDA excluding other
Slide 10: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (₹ mn) Q2 FY23 Q2 FY22 YoY % H1 FY23 H1 FY22 YoY% Income from Operations (Net) 6,139.6 4,589.0 33.8% 11,545.7 10,096.3 14.4% COGS 1,612.1 424.0 280.2% 2,532.0 1,708.7 48.2% Employee Expenses 2,533.3 2,348.0 7.9% 5,097.1 4,738.3 7.6% Other Expenses 1,208.2 824.7
Slide 11: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET Particulars (₹ mn) Sep-22 Mar-22 Particulars (₹ mn) Sep-22 Mar-22 Equity Share Capital 313.6 313.6 Property, plant and equipment 17,044.5 17,429.5 Other Equity 55,226.3 55,175.8 Right to use Lease Assets 2,696.3 2,891.1 Capital Work in Progress 9,845.0 7,548.2 Total - Shar
Slide 12: Revenue Breakup Analysis
REVENUE BREAKUP ANALYSIS Revenues (₹ mn) Q2 FY23 Q2 FY22 YoY % H1 FY23 H1 FY22 YoY% FY22 DCAL India - NCE APIs & Intermediates1 632.2 391.2 61.6% 1,254.7 715.6 75.3% 1,596.8 DCAL India - Quats & Generics1 480.3 333.3 44.1% 994.4 813.2 22.3% 1,852.0 CARBOGEN AMCIS - Contract Research & 4,383.8 3,153.
Slide 13: Revenue Break-up
REVENUE BREAK-UP Total Operating Revenue – Q2 FY23 Total Operating Revenue – H1 FY23 DCAL India - NCE APIs & Intermediates 10.5% 10.9% 10.3% 11.1% DCAL India - Quats & Generics 8.6% 7.8% CARBOGEN AMCIS - Contract Research & Manufacturing 71.4% Services 69.5% CARBOGEN AMCIS - Cholesterol & Vit D Anal
Slide 14: Margin Analysis
MARGIN ANALYSIS EBITDA Margin % Q2 FY23 Q2 FY22 H1 FY23 H1 FY22 FY22 DCAL India - NCE APIs & Intermediates1 6.4% 6.8%* 4.9% 0.4%* - DCAL India - Quats & Generics1 5.1% 7.0% 7.8% 6.1% 7.0% CARBOGEN AMCIS - Contract Research & 14.6%# 20.9% 16.8%# 20.1% 18.2% Manufacturing Services2 CARBOGEN AMCIS - Ch
Slide 15: Q2 FY23 Result Highlights
Q2 FY23 RESULT HIGHLIGHTS Net Revenue at Rs 6,139.6 mn in Q2 FY23 up by 33.8% YoY due to substantial increase in revenue from India and Swiss sites. DCAL India– NCE APIs and Intermediates revenue increased by 61.6% YoY primarily due to: Increased supplies of APIs and intermediates from Bavla site dr
Slide 16: Company Overview
Dishman Carbogen Amcis COMPANY
Slide 17: About Us
ABOUT US Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical co
Slide 18: Key Strengths
KEY STRENGTHS Preferred global outsourcing Upfront investment of more partner with capabilities across the than ₹10,000 mn in large entire CRAMS value chain scale multi-purpose manufacturing capacities Strong chemistry skills The HIPO facility at Bavla, India is the largest HIPO facility in Asia. Di
Slide 19: Manufacturing Facilities
ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: USFDA, MEB, SWISS MEDIC, ANSM, WHO, MFDS, PMDA Superior Chemistry Skills & Capabilities CARBOGEN AMCIS BV., CARBOGEN AMCIS Veenendaal, The Netherlands (Shanghai) Co. Ltd. 28 dedicated R&D labs with multiple shift R&D Chin
Slide 20: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER CLOSE PROXIMITY LARGE SCALE INTEGRATED ACROSS THE STRONG CHEMISTRY TO CLIENTS WITH MANUFACTURING VALUE CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 21: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER CARBOGEN AMCIS (CA) STRONG RESEARCH CAPABILITIES § Focus is on supporting the development process from bench to market § Process research and development to the supply of APIs for preclinical studies, clinical trials and commercial use DISHMAN INDIA STRONG MANUFACTURING CAPAB
Slide 22: Cutting Edge HIPO Capabilities
CUTTING EDGE HIPO CAPABILITIES The HIPO facility at Bavla, India, is one of the kind facility in the world and the largest facility in Asia. The facility has a sound mix of Kilo lab and full- scale manufacturing units to cater to both small volume and large volume orders. State of the art containmen
Slide 23: Therapeutic Area Split
THERAPEUTIC AREA SPLIT DEVELOPMENT COMMERCIAL 22% 21% 28% 32% New Dev Commercials 4% 11% Projects FY22 FY22 4% 18% 17% 11% 14% 6% 6% 4% 4% Cancer ADC-Warhead/ADC Eyes Antibiotic Blood/Immunology Hormone/Metabolism Pain/Nerves Diabetes Various APIs Non-APIs/Intermediates 22
Slide 24: Industry Overview
Dishman Carbogen Amcis INDUSTRY
Slide 25: Top 20 Therapy Areas (US$ bn) - 2026
2026 Expected Global Spending by Therapy Areas Oncology & Immunology expected to dominate sales and grow by 9-12% CAGR through 2026 5-Yr CAGR 2021-2025 Oncologics 306 9-12% Immunology 178 6-9% Antidiabetics 173 Top 20 Therapy Areas (US$ bn) - 2026 6-9% Neurology 151 3-6% Cardiovascular 87 4-7% Antic
Slide 26: Specialty: Market Share & Growth
SPECIALTY: MARKET SHARE & GROWTH Specialty medicines will represent nearly half of global spending in 2025 and almost 60% of total spending in developed markets 59% 47% 45% 41% 37% 38% 35% 28% 29% 24% 21% 21% 17% 14% 9% 10% 2010 2015 2020 2025 Pharmerging Other Developed Global 10 Developed 25 Sourc
Slide 27: For Further Queries
FOR FURTHER QUERIES Mr. Harshil Dalal Mr. Binay Sarda Global CFO Ernst & Young LLP Email: harshil.dalal@dishmangroup.com P: +91 22 6192 0000 Email: binay.sarda@in.ey.com
Dishman Carbogen Amcis — Q2 FY23 Earnings Presentation on 6ix